Altamira Therapeutics Ltd. (CYTO)

NASDAQ: CYTO · IEX Real-Time Price · USD
0.285
+0.017 (6.18%)
At close: Oct 4, 2022 3:57 PM
0.297
+0.012 (4.04%)
After-hours: Oct 4, 2022 4:56 PM EDT
6.18%
Market Cap 5.76M
Revenue (ttm) 70,200
Net Income (ttm) -19.11M
Shares Out 20.19M
EPS (ttm) -1.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 37,840
Open 0.253
Previous Close 0.268
Day's Range 0.251 - 0.288
52-Week Range 0.230 - 3.330
Beta 1.44
Analysts Buy
Price Target n/a
Earnings Date Jul 12, 2022

About CYTO

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, whic... [Read more...]

Industry Biotechnology
IPO Date Aug 6, 2014
CEO Thomas Meyer
Employees 14
Stock Exchange NASDAQ
Ticker Symbol CYTO
Full Company Profile

Financial Performance

Financial numbers in CHF Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Buy
Stock Forecasts

News

Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia

HAMILTON, BERMUDA , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...

1 day ago - GlobeNewsWire

Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis

HAMILTON, BERMUDA , Sept. 27, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announce...

1 week ago - GlobeNewsWire

Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19

HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announce...

3 weeks ago - GlobeNewsWire

Altamira Therapeutics to Host Investor Call on September 14th

HAMILTON, Bermuda, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...

3 weeks ago - GlobeNewsWire

Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit

HAMILTON, BERMUDA , Sept. 08, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medi...

3 weeks ago - GlobeNewsWire

Altamira Therapeutics Provides Business Update

HAMILTON, Bermuda, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a...

1 month ago - GlobeNewsWire

Altamira Therapeutics' CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing...

HAMILTON, BERMUDA , Aug. 03, 2022 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA -- August 3, 2022 -- Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeu...

2 months ago - GlobeNewsWire

Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19

HAMILTON, BERMUDA , Aug. 01, 2022 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / August 1, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important...

2 months ago - GlobeNewsWire

Altamira Therapeutics' Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published i...

•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint de...

2 months ago - GlobeNewsWire

Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary Oligo...

•Company's novel drug development program AM-411 builds on positive animal data •Treatments for rheumatoid arthritis represent the second largest therapeutic area globally •AM-411 to run concurrently wi...

2 months ago - GlobeNewsWire

Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy

Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatments

2 months ago - GlobeNewsWire

Altamira Therapeutic's RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Publ...

Study results appeared in "Biomaterials Advances", a highly respected peer-reviewed journal, showcasing growing medical recognition of Company's patented RNA delivery platform for extrahepatic targets. ...

2 months ago - Accesswire

Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and ...

Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses HAMILTON, BERMUDA / ACCESSWIRE / June...

3 months ago - Accesswire

Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis

Company gains access to the world's largest OTC market for consumer health products Expects substantial and growing US Bentrio revenue contribution over next couple of years HAMILTON, BERMUDA / ACCESSWI...

3 months ago - Accesswire

Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19

Reached targeted clinical trial enrollment of 136 subjects ahead of schedule At current patient enrollment, top-line data read-out is expected in Q3-22 HAMILTON, BERMUDA / ACCESSWIRE / June 23, 2022 / A...

3 months ago - Accesswire

Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo

Significant improvement in balance after four-week treatment with AM-125 20 mg nasal spray vs. placebo Study provides proof-of-concept for enhancement and acceleration of vestibular recovery Treatment w...

3 months ago - Accesswire

Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements

HAMILTON, BERMUDA / ACCESSWIRE / June 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that ...

3 months ago - Accesswire

Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal...

Testing further confirms Bentrio's broad protection against various types of airborne viruses Demonstrates significant reductions in viral load for preventive and mitigative treatment after 4 days vs. s...

3 months ago - Accesswire

Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia

HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that ...

4 months ago - Accesswire

Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray

HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that ...

4 months ago - Accesswire

Altamira's Drug-Free Nasal Spray Shows Benefit In House Dust Mite Study

Altamira Therapeutics Ltd (NASDAQ: CYTO) announced topline data from its clinical trial with Bentrio nasal spray in house dust mite (HDM) allergic rhinitis. The HDM challenge trial demonstrated a statis...

4 months ago - Benzinga

Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House D...

Company's drug-free nasal spray demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls as well as good tolerability and safety HAMILTON, BERMUDA / ACCESSWIRE / May 2...

4 months ago - Accesswire

Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference

HAMILTON, BERMUDA / ACCESSWIRE / May 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that ...

4 months ago - Accesswire

Altamira Therapeutics Issues Shareholder Letter

Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd. (NASDA...

4 months ago - Accesswire

Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-...

Extending clinical study will complement the ongoing trial in Bulgaria Reaffirms it expects to complete the study in 3Q-22 subject to sufficient COVID-19 incidence HAMILTON, BERMUDA / ACCESSWIRE / May 5...

4 months ago - Accesswire